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Abstract
A major mechanism through which cancer cells avoid apoptosis is by promoting the association of 
anti-apoptotic members of the pro-survival Bcl-2 protein family (like Bcl-2 and Bcl-xL) with BH3 
domain-only proteins (like Bim and Bid). Apoptosis and cell proliferation have been shown to be 
linked for many cancers but the molecular basis for this link is far from understood. We have 
identified the Bcl-xL:Bim protein-protein interface as a direct regulator of proliferation and 
apoptosis in pancreatic cancer cells. We were able to predict and subsequently verify 
experimentally the effect of various Bcl-xL single-point mutants (at the position A142) on binding 
to Bim by structural analysis and computational modeling of the inter-residue interactions at the 
Bcl-xL:Bim protein-protein interface. The mutants A142N, A142Q, and A142Y decreased binding 
of Bim to Bcl-xL and A142S increased this binding. The Bcl-xL mutants, with decreased affinity 
for Bim, caused an increase in apoptosis and a corresponding decrease in cell proliferation. 
However, we could prevent these effects by introducing a small interfering RNA (siRNA) targeted 
at Bim. These results show a novel role played by the Bcl-xL:Bim interaction in regulating 
proliferation of pancreatic cancer cells at the expense of apoptosis. This study presents a 
physiologically relevant model of the Bcl-xL:Bim interface that can be used for rational 
therapeutic design for the inhibition of proliferation and cancer cell resistance to apoptosis.
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Apoptosis is a programmed cell death mechanism used by metazoa to get rid of damaged, 
infected or redundant cells, so this process is necessary for the homeostasis of organisms 
from early embryonic development to adult stage and in disease pathologies [1,2]. Apoptosis 
is downregulated in cancer as well as autoimmune diseases and upregulated in degenerative 
diseases [1].
During the past decade, significant progress has been achieved in understanding the 
molecular mechanisms of apoptosis in cancer [3]. The information obtained suggests that the 
commitment to apoptosis occurs through mitochondrial depolarization and release of 
mitochondrial pro-apoptotic factors resulting in activation of caspases, a unique family of 
cysteine proteases. These pathways are all orchestrated by the Bcl-2 (B-cell lymphoma 2) 
family of proteins [4], where different subfamilies not only control apoptosis [5], but also 
other mechanisms of programmed cell death (autophagy, necrosis) [6] and cell proliferation 
[7]. The Bcl-2 family of proteins has been investigated intensively for understanding their 
mechanistic roles in apoptosis. Less is known about their mechanistic roles in proliferation.
The Bcl-2 protein family is especially important for cancer because chemotherapeutic agents 
usually activate cell death involving permeabilization of the mitochondrial outer membrane 
leading to the release of cytochrome c and other apoptogenic factors into the cytosol [4,8,9]. 
Pro-survival Bcl-2 proteins such as Bcl-2, Bcl-xL and Mcl-1 have the potential to hetero-
dimerize with pro-apoptotic members such as Bax, Bak, Bim and Puma through binding of 
the exposed BH3 helix in a groove (dimerization domain) on the surface of anti-apoptotic 
members [4,10]. A major hypothesis in the field is that pro-survival members sequester pro-
apoptotic members by hetero-dimerization resulting in the apoptosis resistant state. The 
potential for therapeutics targeted to Bcl-2 protein interactions is very high considering the 
central importance of the Bcl-2 protein family in regulating the survival and death of cancer 
cells [4].
It is expected that apoptosis should be coupled to cell proliferation and a vast body of 
literature has looked at this coupling directly or indirectly. It has been shown that apoptosis 
and proliferation utilize mechanistically distinct signaling pathways [6], though these 
pathways may intersect. Mathematical models have also been proposed that attempt to tease 
out the balance between apoptosis and proliferation using limited experimental data [11]. 
Multiple studies have also looked directly at the effect of small molecules on apoptosis and 
proliferation in different cancers [12,13,14,15,16]. This is enough to suggest that the 
coupling between apoptosis and cell proliferation is complex and expected to be different in 
different cancers.
The Bcl-2 protein family has been directly implicated in cell proliferation, which is not 
simply due to its anti-apoptotic function [7]. Different members of the Bcl-2 family have 
been shown to play a role in modulating both apoptosis and cell proliferation 
[17,18,19,20,21], but given the large number of proteins in this family that interact with each 
other [4] and the complex coupling between apoptosis and cell proliferation, no simple 
model has emerged to describe this coupling even for specific cancers.
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Structures for most Bcl-2 family members have already been determined experimentally 
using X-ray or NMR techniques. Many structures are also available for protein-protein 
complexes, e.g., Bcl-xL: Bad (PDBid=2bzw), Bcl-xL:Bak peptide (1bxl), Bcl-xL:Bim 
peptide (1pq1), Mcl-1:Noxa (2jm6), Mcl-1:Bim (2nl9). These structures provide a very good 
starting point for our computational method to determine intra-family interactions at the 
atomic level and for predicting interactions between proteins whose complexed structures 
are not available yet.
This study focuses on the interaction between Bcl-xL and Bim, two of the members of the 
Bcl-2 family and how this single interaction can directly affect apoptosis and cell 
proliferation in pancreatic cancer. We developed a computational model representing the 
physiologically relevant dynamic interaction between these two proteins and used the model 
to predict different Bcl-xL mutants with increased and decreased binding for Bim. We then 
validated these predictions experimentally by transfecting cancer cells with mutants to 
determine the effect of the alterations in the Bcl-xL :Bim interaction on proliferation and 
apoptosis in pancreatic cancer.
MATERIALS and METHODS
Computational procedures
Relaxing the protein-protein complex—To understand the functional role of Bcl-
xL:Bim protein-protein interaction, we first validated that the crystal structure of this 
complex is a physiologically relevant model of the interaction. For this validation, we started 
with the crystal structure of this complex from the PDB database (pdbid: 1pq1) and first 
relaxed it through conjugate-gradient minimization using the Dreiding force-field [22].
Computational analysis of protein-protein binding interaction—The protein-
protein interaction surface in the Bcl-xL:Bim was used to identify residues on both Bcl-xLL 
and Bim that line the interaction interface. Each of these residues from Bcl-xL were used in 
an energy analysis to calculate their interaction energy with Bim using the Dreiding force 
field. Corresponding analysis was done for the interface residues from Bim, whose 
interaction energy was calculated with Bcl-xL. The corresponding table of interaction 
energies is included as Table S1 in the supplementary information. Based on this analysis 
and the visual inspection of the Bcl-xL:Bim interface, we selected the Alanine residue 
(A142) in Bcl-xLL as the one to mutate in order to have the greatest impact the Bcl-xL:Bim 
interaction. This residue points directly at Bim (Figure 1A), has a low interaction energy 
with Bim (Table S1) and can be used to modulate the interaction between the two proteins. 
The premise was that if we can predict single-point mutations at the A142 site, designed to 
increase or decrease binding between the two proteins, and confirm it with experiments then 
we would have validated the relaxed (minimized) crystal structure as a good model for 
apoptosis and proliferation related functional studies.
Virtual mutation screening—The A142 position in Bcl-xL was computationally 
mutated to 19 other amino acids using the following protocol. All residues on Bcl-xL and 
Bim proteins in the Bcl-xL:Bim complex that are within 5.0Å of the A142 position are 
selected. The new mutant residue at position 142 and previously selected residues are all 
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optimized at the same time to find the most optimal sidechain orientations for all these 
residues. This rotamer optimization step is performed for all 19 mutants at position 142 and 
the WT complex by using the SCREAM (Side-Chain Rotamer ExcitAtion Method) program 
[23]. SCREAM uses a library of residue conformations ranging from a CRMS diversity of 
0.4Å to 1.6Å in conjunction with a Monte Carlo sampling algorithm using full valence, 
hydrogen bond and electrostatic interactions, but special van der Waals potentials that 
reduce somewhat the penalty for contacts that are slightly too short while retaining the 
normal attractive interactions at full strength. This altered vdW potential enables the use of a 
discrete rotamer library. The resulting structures are relaxed using 25 steps of conjugate 
gradient minimization using the Dreiding force field with normal vdW potential, which is 
able to relax most of the close contacts enabled by SCREAM. The resulting complexes are 




Reagents—Antibodies against Bim and Bcl-xL were from Cell Signaling (Beverly, MA). 
All other chemicals were from Sigma-Aldrich (St. Louis, MO).
Cell culture—Human pancreatic ductal adenocarcinoma cells, the poorly differentiated 
MIA PaCa-2 (CRL-1420) line, was obtained from the American Type Culture Collection 
(Manassas, VA). MIA PaCa-2 cells were grown in 1/1 DMEM/F-12 medium (Gibco 
Invitrogen Corporation, Grand Island, NY) supplemented with 15% FBS, 4 mM L-
glutamine, and antibiotic/ antimicotic solution (Omega Scientific, Tarzana, CA). Cells were 
maintained at 37 °C in a humidified atmosphere containing 5% CO2 and used between 
passages 3 and 9. For the experiments, MIA PaCa-2 cells were cultured for 48 h.
Plasmids construction—Bcl-xL wild type (wt) plasmid was synthesized by DNA 
amplification by PCR using human cDNA as template and cloning into the pcDNA3.1 
vector (Genescript, Piscataway, NJ). Bcl-xL mutants were synthesized by inducing point 
mutation in the Bcl-xL wt plasmid (Genescript, Piscataway, NJ).
Transfections—Transient transfections of MIA PaCa-2 cells were performed using the 
electroporation Amaxa System Nucleofector™ (Amaxa Inc, Gaithersburg, MD) according 
to the manufacturer protocol. 2μg of each plasmid was applied to 2 million cells. Control 
cells were transfected with the empty vector pcDNA3.1 (Ambion, Foster City, CA).
In vitro Proliferation—Proliferation was assessed by measuring the level of 3H-thymidine 
incorporation into DNA in cells cultured for 48h [24].
Measurement of apoptosis—Internucleosomal DNA fragmentation in cultured cells 
was measured by using Cell Death Detection ELISAPlus kit (Roche Molecular 
Biochemicals, Manheim, Germany) according to the manufacturer’s instructions [25].
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Western Blot Analysis—Cells were lysed in radioimmune precipitation phosphorylation 
buffer (50 mM NaCl, 50 mM Tris/HCl, pH 7.2, 1% deoxycholic acid, 1% Triton X-100, 
0.1% SDS, 10 mM Na2HPO4 + NaH2PO4, 100 mM NaF, 2 mM Na3VO4, 80 μM 
glycerophosphate, 20% glycerol, 1 mM phenylmethylsulfonyl fluoride (PMSF), 5 μg/ml 
each of pepstatin, leupeptin, chymostatin, antipain, and aprotinin), sonicated, and 
centrifuged for 15 min at 16,000 × g at 4 °C. Proteins were separated by SDS-PAGE and 
electrophoretically transferred to nitrocellulose or PVDF membranes. Nonspecific binding 
was blocked for 1 h with 5% bovine serum albumin or nonfat dry milk in Tris-buffered 
saline (4 mM Tris base, 100 mM NaCl, pH 7.5) containing 0.05% Tween 20. Membranes 
were incubated with primary antibody for 2 h and then for 1 h with peroxidase-conjugated 
secondary antibody. Blots were developed using the SuperSignal chemiluminescent 
substrate (Pierce).
Immunoprecipitation—Cells were collected, washed twice in a buffer containing 20 mM 
Tris (pH 7.5) and 10 mM DTT, and then resuspended in a lysis buffer (50 mM Tris-HCl, 
150 mM NaCl, 2 mM EGTA, 10 μg/ml each of leupeptin and aprotinin, 1 mM PMSF, 1% 
IGEPAL CA-630), and sonicated for 30 s. The lysates were clarified by centrifugation, and 
1mg of protein was subjected to immunoprecipitation with the indicated antibodies at room 
temperature according to the Catch and Release immunoprecipitation kit (Upstate Biotech 
Millipore, Temecula, CA) [26]. In this and other assays, protein concentration was measured 
by the Bradford assay (Bio-Rad Laboratories).
RESULTS
Validation of physiologically relevant structure for the Bcl-xL:Bim complex
As described in the methods section, the residue A142 was selected to predict mutations that 
will modulate the binding between Bcl-xL and Bim in the complex. This residue was 
mutated to 19 other amino acids, the local sidechains optimized, and the resulting complex 
minimized as described in the methods section. The interaction energy between Bcl-xL and 
Bim was obtained for each of these mutants using the Dreiding force field [22]. This energy 
is shown in Table 1 relative to the interaction energy in the WT complex. The table also 
breaks up the interaction energy into its Coulombic, van der Waals and hydrogen bond (H-
Bond) components, as the Dreiding force field contains a hydrogen bond term.
As seen in Table 1, the mutants containing amino acids with charged (R, K, D, E) and bulky 
(W, Y) sidechains lead to the greatest modulation of the binding energy between Bcl-xL and 
Bim. In order to experimentally test these predictions to validate the structure, we selected 
one mutant A142S that increased binding energy. Of note, there were three mutants (A142S, 
A142R, A142K) that significantly increased binding energy, but we wanted to avoid 
mutations based on charged residues, so A142R and A142K were not used for experimental 
testing. The A142S mutant actually gains hydrogen bond forces between the serine hydroxyl 
hydrogen and the backbone carbonyl of the L94 residue on Bim protein as shown in Figure 
1B. This increased binding energy is also demonstrated in Table 1 which shows a -3.3 
kcal/mol hydrogen bond contribution dominating the overall interaction energy gain of -3.0 
Abrol et al. Page 5









kcal/mol., as a serine amino acid side chain is closest in size to the wild-type alanine side 
chain.
The three single-point mutations (A142Q, A142Y, A142N) were also selected for 
experimental testing that were predicted to decrease binding of Bcl-xL to Bim. The relative 
predicted ordering of binding interaction between Bcl-xL and Bim is the following:
This relative ordering is based on a purely enthalpic contribution to binding interaction 
between Bcl-xL and Bim, so entropic change upon Bcl-xL mutant binding to Bim (relative 
to WT) is being ignored as an approximation. These mutants were experimentally tested for 
Bcl-xL:Bim binding and the results are presented in Figure 2A. Mutants A142Q, Y and N 
showed decrease in the level of Bim binding. Whereas, mutant A142S showed increase in 
Bim binding confirming the predicted trend for the mutants.
Functional consequences of Bcl-xL:Bim binding
The structurally validated Bcl-xL:Bim complex and four mutants were studied for their 
effect on cell proliferation and apoptosis. First, we found that transfection of MIA PaCa-2 
cells with Bcl-xL WT stimulated cell proliferation (Figure 2B). The mutant A142S, which, 
showed increase in Bcl-xL:Bim binding stimulated proliferation at a level similar to Bcl-xL 
WT plasmid. Further, transfection with mutants A142Q and A142Y, which, decreased Bim 
binding to Bcl-xL prevented the stimulation of proliferation induced by Bcl-xL WT (Figure 
2B). Bim inhibition using Bim siRNA prevented the pro-proliferation effect of Bcl-xL WT 
and A142S mutant indicating that Bim is needed for inducing proliferation of MIA PaCa-2 
cells through interacting with Bcl-xL (Figure 2B).
Differently from proliferation, Bcl-xL WT and A142S mutant transfections did not affect 
apoptosis (Figure 2C). However, transfection with A142Q, A142Y and A142N mutants 
stimulated apoptosis. Figures 2B and 2C show a strong correlation between the effects of 
Bcl-xL mutations on proliferation and apoptosis.
DISCUSSION
The interaction of Bcl-xL with Bim has been shown to be one of the important interactions 
in the Bcl-2 family that affects apoptosis [4]. Bcl-xL or Bim knockout experiments do not 
explore the effect of binding strength between the two protein partners on apoptosis or 
another cellular function of interest.
The availability of three forms of this protein-protein complex allows for a functional 
evaluation of the role played by this binding in apoptosis and cell proliferation. The overall 
study provides a valuable tool to characterize the effect of protein-protein interactions on 
cellular function that doesn’t rely on simply knocking out one of the partners in the 
interaction, which provides much less insight. It uses a chemically modulated (via 
mutations) binding gradient to truly assess the role of the interaction strength between the 
protein partners (Bcl-xL and Bim) on apoptosis and cell proliferation. This molecular level 
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understanding of the Bcl-xL:Bim interaction also provides a promising approach for tackling 
pancreatic cancer and other cancers as any therapeutic agent targeting the Bcl-xL:Bim 
binding interface on Bcl-xL will be capable of causing apoptosis while preventing cell 
proliferation.
Systematic mutational analysis of protein-protein interaction surfaces has been normally 
used to assess the effect of protein-protein binding on function for other protein-protein 
systems [27]. This is a very resource-intensive exercise to characterize the protein-protein 
interface. A more efficient method is the one presented here where structural predictions 
guide the experiments to first find mutants that lead to a mutant protein-protein complexes 
with differential binding. Then these mutants are used in functional studies to characterize 
the importance on this binding strength on function.
Table 1 and Figure 1A show results for Bcl-xL mutants that exhibit differential binding 
towards Bim. Four mutants were selected to sample the protein-protein binding energy 
landscape. The A142S Bcl-xL mutant exhibited increased binding for Bim (relative to WT 
Bcl-xL), and the other three mutants (A142N, A142Q, A142Y) exhibited decreased relative 
binding for Bim (relative to WT Bcl-xL). The serine residue is the closest in size to alanine 
(except glycine) among the 20 amino acids, so it had the best chance to fit sterically in the 
protein-protein interface. In addition, it gained a hydrogen bonding interaction with the 
backbone carbonyl oxygen of L94 residue on Bim, which allowed Bcl-xL to increase its 
binding strength for Bim. All other residues are larger than Serine and produced a net 
repulsive interaction with Bim. These results were confirmed experimentally and show that 
we can chemically alter (using mutations) protein-protein interactions in a predictive manner 
resulting in protein-protein complexes displaying a range of relative binding affinities. This 
in turn enabled the characterization of protein-protein binding strength on cellular functions 
of interest to us like apoptosis and proliferation.
We found that transfection of the cancer cells with Bcl-xL mutants with decreased binding 
affinity for Bim relative to WT Bcl-xL (A142Q and A142Y) show decreased proliferation 
than WT or A142S mutant. This differential effect on proliferation is abolished upon the use 
of Bim siRNA. This data strongly suggests that direct interaction of Bcl-xL with Bim is 
responsible for the regulation of cell proliferation. Transfection of cancer cells with mutants 
with decreased Bcl-xL:Bim binding (A142N, A142Q, A142Y) resulted in greater apoptosis 
rates whereas A142S and WT showed similar apoptosis levels.
This data is cumulatively summarized in Figure 3 through a model, which shows that 
decreasing the binding of Bcl-xL to Bim provides a double benefit of promoting apoptosis 
and reducing pancreatic cancer cell proliferation. In addition, it shows that transfections with 
A142S which increased binding to Bim did not result in significant effects on apoptosis or 
proliferation compared to transfection with WT. We speculate that this occurred because 
transfection with WT itself increased cellular expression of Bcl-xL sufficiently to effect 
maximal responses on downstream signaling for proliferation and apoptosis.
The Bcl-2 family of proteins has been shown to be a key player in apoptotic pathways. This 
study shows that at least in pancreatic cancer cells, a key Bcl-2 family interaction (Bcl-
Abrol et al. Page 7









xL:Bim) can also directly control proliferation. These findings make the Bcl-xL:Bim 
complex and the binding interface a promising therapeutic target for pancreatic cancer, 
whose disruption will provide a dual benefit of increased apoptosis and decreased cell 
proliferation. Cell proliferation can be caused by numerous biochemical signaling pathways. 
How these pathways interact with Bcl-xL or Bim is currently being investigated.
This study also exemplifies the use of computational predictions to guide biological 
investigations, as it not only provides vital structural insights but also testing a handful of 
predicted mutations consumes much less resources than doing multiple-residue scanning 
mutagenesismaking efficient use of experimental resources.
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• Direct role of Bcl-2 protein interactions in cell proliferation is not clear.
• Designed Bcl-xL mutants show opposite effects on apoptosis and proliferation.
• Disrupting Bcl-xL:Bim interaction increased apoptosis in pancreatic cancer.
• Disrupting Bcl-xL:Bim interaction decreased proliferation in pancreatic cancer.
• Bcl-xL:Bim interaction can control both apoptosis and proliferation.
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A) Bcl-xL:Bim complex from PDBid:1pq1. Residue A142 on Bcl-xL is shown with van der 
Waals spheres. B) A142S mutant makes a hydrogen bond with backbone of L94 on Bim.
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A) A142S mutation increases the level of Bim binding to Bcl-xL. Mutations A142Q/Y/N 
decrease binding of Bim to Bcl-xL MIA PaCa-2 pancreatic cancer cells were transfected 
using electroporation and cultured for 48h. Binding of Bim to Bcl-xL was assessed by 
measuring the level of Bim present in Bcl-xL immuno-precipitate by Western. B) Bim 
siRNA prevented the increase in proliferation induced by Bcl-xL wt and Bcl-xL A142S 
suggesting that Bim is necessary for the pro-proliferation effect of Bcl-xL. MIA PaCa-2 
pancreatic cancer cells were transfected using electroporation and cultured for 48h. 
Proliferation was assessed by measuring H-Thymidine incorporation into DNA. *, p < 0.05 
versus pcDNA3.1; #, p < 0.05 versus Bcl-xL WT. C) Bcl-xL wt and A142S did not affect 
apoptosis; whereas, A142Q/Y/N stimulated apoptosis. MIA PaCa-2 pancreatic cancer cells 
were transfected using electroporation and cultured for 48h. Apoptosis was assessed by 
measuring DNA fragmentation by ELISA. *, p < 0.05 versus pcDNA3.1.
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Model summarizing the effect of Bcl-xL:Bim interaction strength on apoptosis (green plus) 
and proliferation (red cross) for Mutant↓ of Bcl-xL (that decreases Bcl-xL:Bim binding) and 
Mutant↑ of Bcl-xL (that increases Bcl-xL:Bim binding) relative to WT Bcl-xL.
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Table 1
Predicted energies of interaction (in kcal/mol) between Bcl-xL mutants and Bim, relative to that for WT Bcl-
xL.
Mutant Energy Coulomb H-Bond vdW
WT 0.0 0.0 0.0 0.0
A142C -0.7 -0.3 0.0 -0.4
A142D 19.2 16.0 0.0 3.2
A142E 20.9 15.8 0.1 5.0
A142F 19.3 0.7 0.2 18.3
A142G 1.5 0.0 0.0 1.5
A142H 12.8 -1.1 0.1 13.8
A142I 7.0 0.8 0.1 6.1
A142K -2.6 -20.6 0.2 17.8
A142L 8.5 0.7 0.1 7.6
A142M 8.0 0.5 0.2 7.3
A142N 3.0 0.5 0.1 2.4
A142P 2.1 0.5 0.2 1.4
A142Q 3.8 -1.5 -5.0 10.3
A142R -8.0 -16.8 0.2 8.6
A142S -3.0 -0.6 -3.3 0.9
A142T 0.3 0.1 -1.1 1.3
A142V 4.6 0.4 0.1 4.1
A142W 20.9 0.8 0.4 19.7
A142Y 24.1 1.6 0.3 22.3
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